Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000879 · ClinicalTrials.gov registry record · Phase 1
A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00000879 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 48 participants.
The verdict
NCT00000879, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving the ALVAC vCP1452 anti-HIV vaccine alone or with another vaccine called AIDSVAX B/B to babies of HIV-positive mothers is safe. The study will also look at how these vaccines affect a baby's immune system. Most HIV-positive children get HIV from their mothers during pregnancy or birth. Treatment with anti-HIV drugs can reduce the baby's risk of getting HIV. Vaccines also may help prevent HIV infection. This study will look at whether the ALVAC vCP1452 vaccine and the AIDSVAX B/B vaccine can help the body fight off HIV infection. There is no chance of getting HIV infection from the vaccines. (This study has been changed. In earlier versions, ALVAC vCP205 and AIDSVAX B/E were going to be used.)
Interventions
- BIOLOGICAL ALVAC(2)120(B,MN)GNP (vCP1452)
- BIOLOGICAL MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
- BIOLOGICAL ALVAC-HIV MN120TMG (vCP205)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Est. Completion | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000879
The ClinicalTrials.gov registry entry for NCT00000879 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ALVAC(2)120(B,MN)GNP (vCP1452) is the first listed.
NCT00000879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000879 about?
NCT00000879 is a clinical study titled "A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers". The purpose of this study is to see if giving the ALVAC vCP1452 anti-HIV vaccine alone or with another vaccine called AIDSVAX B/B to babies of HIV-positive mothers is safe. The study will also look at how these vaccines affect a baby's immune system. Most HIV-positive children get HIV from their mot...
What is the current status of trial NCT00000879?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00000879?
The interventions under investigation include: ALVAC(2)120(B,MN)GNP (vCP1452) (BIOLOGICAL), MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 (BIOLOGICAL), ALVAC-HIV MN120TMG (vCP205) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00000879?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.